Pharmacotherapy of Prograf (Tacrolimus) in Liver Transplant Recipients; Consideration of Its' Levels with Efficacy and Toxicity

Author Information
Article Notes and Dates
To Cite : Tolou-Ghamari Z. Pharmacotherapy of Prograf (Tacrolimus) in Liver Transplant Recipients; Consideration of Its' Levels with Efficacy and Toxicity, Jundishapur J Helath Res. 2017 ;8(1):e44653. doi: 10.5812/jjhr.44653.
Abstract
1. Context
2. Evidence Acquisition
3. Survey Method
4. Results
5. Discussion
Acknowledgements
References
  • 1. Tolou-Ghamari Z. Monitoring tacrolimus (fk506) in liver transplant recipients: A consideration of alternative techniques and the influence of clinical status. 1999;
  • 2. Mika A, Stepnowski P. Current methods of the analysis of immunosuppressive agents in clinical materials: A review. J Pharm Biomed Anal. 2016; 5(127): 207-31
  • 3. Tolou-Ghamari Z, Palizban A, Wendon J, Tredger J. Pharmacokinetics of Tacrolimus Immediately after Liver Transplantation. Transplantationmedizine. 2004; 112: 116
  • 4. Zegarska J, Hryniewiecka E, Zochowska D, Samborowska E, Jazwiec R, Borowiec A, et al. Tacrolimus metabolite m-iii may have nephrotoxic and myelotoxic effects and increase the incidence of infections in kidney transplant recipients. Transplant Proc. 2016; 48(5): 1539-42
  • 5. Tolou-Ghamari Z, Palizban AA. The history of liver and renal transplantation. Internet J Pharmacol. 2003;
  • 6. Venkataramanan R, Warty VS, Zemaitis MA, Sanghvi AT, Burckart GJ, Seltman H, et al. Biopharmaceutical aspects of FK-506. Transplant Proc. 1987; 19(5 Suppl 6): 30-5[PubMed]
  • 7. Yoshimura N, Matsui S, Hamashima T, Lee CJ, Oka T. A new immunosuppressive agent, FK506, inhibits the expression of alloantigen-activated suppressor cells as well as the induction of alloreactivity. Transplant Proc. 1989; 21(1 Pt 1): 1045-7[PubMed]
  • 8. Christians U, Braun F, Kosian N, Schmidt M, Schiebel HM, Ernst L, et al. High performance liquid chromatography/mass spectrometry of FK 506 and its metabolites in blood, bile, and urine of liver grafted patients. Transplant Proc. 1991; 23(6): 2741-4[PubMed]
  • 9. Sattler M, Guengerich FP, Yun CH, Christians U, Sewing KF. Cytochrome P-450 3A enzymes are responsible for biotransformation of FK506 and rapamycin in man and rat. Drug Metab Dispos. 1992; 20(5): 753-61[PubMed]
  • 10. Tolou-Ghamari Z, Palizban AA, Gharavi M. Cyclosporin trough concentration-rejection relationship after kidney transplantation. Indian J Pharmacol. 2003; 35(6): 395-6
  • 11. Tolou-Ghamari Z, Palizban AA, Tredger JM. Modelling tacrolimus AUC in acute and chronic liver disease immediately after transplant. Transplantationmedizine 2004; 16-11
  • 12. Hosohata K, Uesugi M, Hashi S, Hosokawa M, Inui K, Matsubara K, et al. Association between CYP3A5 genotypes in graft liver and increase in tacrolimus biotransformation from steroid treatment in living-donor liver transplant patients. Drug Metab Pharmacokinet. 2014; 29(1): 83-9[PubMed]
  • 13. Yoon SH, Cho JH, Kwon O, Choi JY, Park SH, Kim YL, et al. CYP3A and ABCB1 genetic polymorphisms on the pharmacokinetics and pharmacodynamics of tacrolimus and its metabolites (M-I and M-III). Transplantation. 2013; 95(6): 828-34[DOI][PubMed]
  • 14. Chitnis SD, Ogasawara K, Schniedewind B, Gohh RY, Christians U, Akhlaghi F. Concentration of tacrolimus and major metabolites in kidney transplant recipients as a function of diabetes mellitus and cytochrome P450 3A gene polymorphism. Xenobiotica. 2013; 43(7): 641-9[DOI][PubMed]
  • 15. Hirano K, Naito T, Mino Y, Takayama T, Ozono S, Kawakami J. Impact of CYP3A5 genetic polymorphism on cross-reactivity in tacrolimus chemiluminescent immunoassay in kidney transplant recipients. Clin Chim Acta. 2012; 414: 120-4[DOI][PubMed]
  • 16. Shimomura M, Masuda S, Goto M, Katsura T, Kiuchi T, Ogura Y, et al. Required transient dose escalation of tacrolimus in living-donor liver transplant recipients with high concentrations of a minor metabolite M-II in bile. Drug Metab Pharmacokinet. 2008; 23(5): 313-7[PubMed]
  • 17. Kuypers DR, de Jonge H, Naesens M, Lerut E, Verbeke K, Vanrenterghem Y. CYP3A5 and CYP3A4 but not MDR1 single-nucleotide polymorphisms determine long-term tacrolimus disposition and drug-related nephrotoxicity in renal recipients. Clin Pharmacol Ther. 2007; 82(6): 711-25[DOI][PubMed]
  • 18. Kuypers DR. Immunosuppressive drug monitoring - what to use in clinical practice today to improve renal graft outcome. Transpl Int. 2005; 18(2): 140-50[DOI][PubMed]
  • 19. Tolou-Ghamari Z, Mortazavi M, Palizban AA, Najafi MR. The investigation of correlation between Iminoral concentration and neurotoxic levels after kidney transplantation. Adv Biomed Res. 2015; 4: 59[DOI][PubMed]
  • 20. Tolou_Ghamari Z, Palizban AA. Kidney transplant recipients and the incidence of adverse reactions to cyclosporin. Saudi Med J. 2004; 25(10)
  • 21. Tolou-Ghamari Z, Sanei B. Prograf concentrations in liver transplantation: Correlation with headache and other neurotoxic complications? Thrita. 2016; 5(1)
  • 22. Tolou-Ghamari Z, Palizban AA, Tredger JM. Clinical monitoring of tacrolimus after liver transplantation using pentamer formation assay and microparticle enzyme immunoass Drugs in R & D. 2004; 5(1): 17-22
  • 23. Shaygannejad V, Tolou-Ghamari Z. What is the Real Fate of Vitamin D in Multiple Sclerosis? Int J Prev Med. 2013; 4
  • 24. Tolou-Ghamari Z, Najafi MR, Mehavari Habibabadi J, Zare M. Preliminarily analysis of carbamazepine (CBZ) C0 in patients visited Isfahan Epileptic Clinics. Int J of Preventive Med. 8 S343 th Iranian Neurology Congress 2013; 4
  • 25. Tolou-Ghamari Z. Efficacy and toxicity of rituximab in multiple sclerosis. Archives of Neuroscience 2016; 3(1)[DOI]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Cited By:

Jentashapir Journal of Health Research accepts terms & conditions of:

International Committee of Medical Journal Editors (ICMJE) Citedby Linking DOI enabled Crossref iThenticate COPE Cross Check